Related coverage linked through entity extraction aliases.
Feb 20, 2026
Private prescriptions for GLP-1 weight-loss drugs in England are concentrated in affluent areas despite higher obesity rates in deprived regions. Online pharmacies face scrutiny for inadequate verification checks when dispensing these medications.
Feb 20, 2026
Novo Nordisk's next-generation obesity drug CagriSema achieved 23% weight reduction compared to 25.5% for Eli Lilly's tirzepatide in an 84-week trial, sending Novo shares down 15% and erasing over $400 billion in market value since 2024.
Feb 14, 2026
A 30-year-old female with stage IV gallbladder adenocarcinoma achieved complete metabolic resolution of metastases after three cycles of pembrolizumab, gemcitabine, and cisplatin, despite presenting without traditional risk factors.
Feb 16, 2026
Weight-loss drugs like Ozempic and Wegovy are creating visible facial changes in celebrities while scams targeting consumers surge nationwide. Multiple public figures have disclosed using GLP-1 medications, with some experiencing significant side effects.
Feb 18, 2026
Eli Lilly is developing multiple next-generation obesity treatments, including oral GLP-1 drug orforglipron expected to launch in Q2 2026, as competition intensifies in a market projected to reach $95 billion by 2030.
Feb 15, 2026
Recent reviews highlight expanding clinical benefits of GLP-1-based therapies, including antiinflammatory actions across multiple organs and cardiovascular risk reduction, with combination approaches emerging for obesity treatment.
Feb 17, 2026
Novo Nordisk secured FDA approval for oral Wegovy tablets in December 2025 and subsequently sued telehealth company Hims & Hers for patent infringement over compounded versions. The company is the only manufacturer with an FDA-approved GLP-1 weight loss pill.
Feb 21, 2026
New research reveals semaglutide may directly repair cartilage in osteoarthritis patients, while a separate study raises concerns about SNAC, an ingredient used in oral semaglutide formulations, and its effects on gut health.
Feb 20, 2026
Tirzepatide, the active ingredient in Mounjaro, reduced alcohol intake by more than half in animal models and prevented relapse-like drinking behaviors, offering potential insights for alcohol use disorder treatment.
Feb 16, 2026
The FDA approved an oral version of Wegovy in December 2025, providing a pill alternative to injections. Clinical trials showed comparable effectiveness between oral and injectable forms of semaglutide for weight loss.
Feb 18, 2026
GLP-1 weight loss drugs show increasing efficacy but raise concerns about excessive weight loss, side effects, and the rise of unregulated compounded versions sold online.
Feb 17, 2026
Semaglutide and other GLP-1 receptor agonists demonstrate substantial weight loss effectiveness through appetite regulation and blood sugar control, with clinical studies showing average reductions of 14.9% to 20.9% body weight.
Feb 19, 2026
Online telehealth company Hims & Hers withdrew plans to offer a $49 compounded oral semaglutide pill after FDA Commissioner Marty Makary called such products "illegal copycats" and Novo Nordisk filed a patent infringement lawsuit.
Feb 18, 2026
A University of South Australia study finds salcaprozate sodium (SNAC), the compound enabling oral semaglutide tablets to work, may alter gut bacteria and increase inflammatory markers in rats, though human effects remain unclear.
Feb 18, 2026
Dr. Reddy's Laboratories is poised to launch generic oral and injectable semaglutide in India following regulatory approval, targeting a market projected to exceed $1 billion driven by 100 million diabetics.
Feb 18, 2026
European regulators approved a 7.2mg "megadose" of Novo Nordisk's Wegovy involving three weekly injections. The Danish drugmaker filed suit against Hims & Hers after the telehealth company briefly launched a compounded oral semaglutide product.
Feb 18, 2026
The European Commission has authorized a new 7.2 mg once-weekly dose of Wegovy (semaglutide) for adults with obesity across all 27 EU member states, following positive opinion from the EMA's scientific committee in December 2025.
Feb 17, 2026
Novo Nordisk's investigational dual agonist CagriSema demonstrated superior efficacy to Ozempic in a phase 3 trial for type 2 diabetes patients, while the company faces market share losses to Eli Lilly in the GLP-1 space.
Feb 17, 2026
Novo Nordisk announced on February 4, 2026, that oral semaglutide previously marketed as Rybelsus will be rebranded as oral Ozempic, with availability expected in Q2 2026. The company also filed a patent infringement lawsuit against Hims & Hers over compounded oral semaglutide products.
Feb 16, 2026
Natco Pharma received CDSCO approval to manufacture and launch generic semaglutide injection in India next month for type 2 diabetes treatment, sending shares up over 11% on Monday.
